Tvardi Therapeutics, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Tvardi reported positive topline results from a healthy volunteer study of TTI-109, a next-generation STAT3 inhibitor, demonstrating improved tolerability and reduced disease-relevant immune cell populations compared to TTI-101. The company selected ulcerative colitis (UC) as the initial indication for TTI-109, representing a $3B US/$9B global addressable market. Cash position declined to $15.8M (June 30, 2026) from $30.8M (December 31, 2025); the company projects runway through Q3 2027 but notes TTI-109 UC development requires additional funding and IND clearance, with trial initiation targeted for 2027.
Why this rating
Positive clinical signal and indication selection represent progress for a $207M company, but meaningful cash burn ($15M runway) and funding dependency constrain upside trajectory.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.